The systemic availability of buprenorphine administered by nasal spray.
The kinetics and systemic bioavailability of intranasally administered buprenorphine have been investigated in 9 healthy volunteers in an intranasal/intravenous cross-over study. Each subject received a nominal 0.3 mg dose of buprenorphine intranasally followed one week later by a matched dose intravenously. For the intranasal administration mean tmax and mean Cmax were 30.6 min and 1.77 ng mL-1, respectively. Mean intranasal bioavailability was 48.2 +/- 8.35% (mean +/- s.e.m.) of the intravenous value. Intranasal administration may represent a valuable new delivery route for buprenorphine.
Eriksen
J
J
Pain Clinic, Bispebjerg Hospital, Copenhagen, Denmark.
Jensen
N H
NH
Kamp-Jensen
M
M
Bjarnø
H
H
Friis
P
P
Brewster
D
D
D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D000336:Aerosols; D001682:Biological Availability; D002047:Buprenorphine / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male
D000336:Aerosols; D002047:Buprenorphine